Advances in liver disease. Highlights from the 56th Annual Meeting of the American Association for the Study of Liver Diseases, November 11-November 15, 2005, San Francisco, CA

Reviews in Gastroenterological Disorders

Volumn 6, Issue 1, 2006, Pages 48-61

  Davis, Gary L ^a   Keeffe, Emmet B ^b   Balart, Luis A ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; End stage liver disease; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Liver transplantation

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CAFFEINE; CHOLIC ACID; CLEVUDINE; ENTECAVIR; ERYTHROPOIETIN; HEPATITIS C VACCINE; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; LIDOCAINE; NM 283; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHENAZONE; PLACEBO; PRADEFOVIR; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCH 50304; TELBIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; VX 950;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ASIAN AMERICAN; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG POTENTIATION; ESOPHAGUS VARICES; FATTY LIVER; HEALTH BEHAVIOR; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NEPHROTOXICITY; NONHUMAN; OBESITY; PREVALENCE; TREATMENT PLANNING; UNITED STATES;

EID: 33645083230     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
2. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl. 2003; 9:331-338.
3. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate [abstract 44]. Hepatology. 2005;42:213A.
4. Hoyumpa A, Sharkey FE, Brock PS, et al. Greater prevalence of cirrhosis in Hispanics than Caucasians or African-Americans [abstract 622]. Hepatology. 2005;42:442A.
5. Verma S, Bonacini M, Govindarajan S, et al. Hispanic race/ethnicity is associated with an aggressive course of chronic hepatitis C infection: role of patient demographics, hepatic steatosis and necroinflammation [abstract 624]. Hepatology. 2005;42:442A.
6. Bruno S, Stroffolini T, Benvegnu L, et al. Long-term outcome of patients with HCV-related, Child's class A cirrhosis treated with Interferon-alpha (IFN): the impact of sustained virologic response (SVR) on hepatocellular carcinoma (HCC) occurrence and mortality [abstract 85]. Hepatology. 2005;42:229A.
7. Everson G, Shiffman M, Sterling RK, et al. Hepatic function improves after sustained virologic response in hepatitis C patients with advanced fibrosis and cirrhosis: results of the lead-in phase of the HALT-C trial [abstract 1265]. Hepatology. 2005;42:697A.
8. Leevy C, Chalmers C, Blatt LM. Comparison of African American and non-African American patient end-of-treatment response for Peg-IFN alfa-2 and weight-based ribavirin non-responders retreated with IFN Alfacon-1 and weight-based ribavirin abstract 1721. Hepatology. 2004;40:240A.
9. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38: 645-652.
10. Gross J, Johnson S, Kwo P, et al. Double-dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon/ribavirin non-resporiders with hepatitis C: final results of "RENEW" [abstract 60]. Hepatology. 2005;42: 219A-220A.
11. Shiffman ML, Price A, Hubbard S, et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and Epoetin alfa (EPO) enhances sustained virologic response (SVR) [abstract 55]. Hepatology. 2005;42:217A.
12. Foy E, Li Y, Sumpter R, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-1 signaling. PNAS. 2005;102:2986-2991.
13. Gale M, Foy E. Evasion of intracellular host defense by hepatitis C virus. Nature. 2005;436: 939-945.
14. Reesink HW, Zeuzum S, Weegink S, et al. Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor [abstract 86]. Hepatology. 2005;42:234A-235A.
15. Zeuzem S, Sarrazin C, Rozier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (Peg-IFN-alpha) [abstract 94]. Hepatology. 2005;42:233A.
16. Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus PEG-Intron in hepatitis C genotype-1 PEG-Intron non-responders: phase 1b results [abstract 201]. Hepatology. 2005;42: 276A.
17. Sarrazin C, Kieffer T, Bartels D, et al. Characterization of viral variant in the HCV NS3 protease domain of genotype 1 patients that are selected during 14 days of dosing with VX-950 [abstract LB06]. Hepatology. 2005;42:751A.
18. O'Brien C, Godofsky E, Rodriquez-Torres M, et al. Randomized trial of valopicitabine (NM283), alone or with Peg-interferon versus retreatment with Peg-interferon plus ribavirin (PegIFN/RBV) in hepatitis C patients with previous non-response to PegIFN/RBV: first interim results [abstract 95]. Hepatology. 2005; 42:234A.
19. DiBisceglie A, Frey S, Gorse FJ, et al. Phase I safety and immunogenicity trial of a novel E1E2/AU59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults [abstract LB05]. Hepatology. 2005;42:750A.
20. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522-527.
21. Jensen D, Morgan T, Marcellin P, et al. Rapid virological response at week 4 (RVR) of peginterferon alfa-2a (40KD) (PEGASYS(r)) plus ribavirin (RBV, COPEGUS(r)) treatment predicts sustained virological response (SVR) after 24 weeks in genotype 1 patients [abstract 1155]. Hepatology. 2005;42:650A.
22. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
23. Ferenci P, Bergholz U, Laferl H, et al. Is shorter treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) possible in HCV genotype 1 'super-responders'? Preliminary results of a prospective randomized clinical trial [abstract 56]. Hepatology. 2005;42: 218A.
24. Manns MP, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet. 2001; 358:958-965.
25. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
26. Keeffe EB, Dieterich DT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the U. S. Clin Gastroenterol Hepatol. 2004;2:87-106.
27. Sherman A, Tsang T, Villaneuva G, et al. Mass screenings in New York City reveal extraordinarily high prevalence of hepatitis B in an urban Asian population [abstract 47]. Hepatology. 2005;42(suppl 1):214A.
28. Perrillo RP, Gish R, Peters M, et al. A critical appraisal of current approaches to treatment of chronic hepatitis B (CHB) based on a review by an international panel of investigators and survey of AASLD membership [abstract 218]. Hepatology. 2005;42(suppl 1):283A-284A.
29. Prati D, Taloli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137:1-10.
30. Kim HC, Nam CN, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver disease: prospective cohort study. BMJ. 2004;328:983.
31. Wang C, Deubner H, Shuhart M, et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection [abstract 961]. Hepatology. 2005;42(suppl 1): 573A.
32. Nguyen MH, Trinh H, Garcia RT, et al. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation [abstract 1008]. Hepatology. 2005;42(suppl 1):593A.
33. Lai M, Hyatt B, Afdahl N. Role of liver biopsy in patients with normal ALT and high HBV DNA [abstract 1322]. Hepatology. 2005;42(suppl 1): 720A.
34. Hadziyannis S, Tassopoulos N, Chang TT, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy [abstract LB14]. Hepatology. 2005;42(suppl 1):754A.
35. Lee YS, Suh DJ, Lim YS, et al. Emergence of rtA181V/T and rtN236T mutations after 48 weeks of adefovir dipivoxil therapy in patients with lamivudine-resistant chronic hepatitis B [abstract 972]. Hepatology. 2005;42(suppl 1): 578A.
36. Lok AS, Fung SK, Han SH, et al. Virological response and resistance to adefovir (ADV) therapy in liver transplant (OLT) patients [abstract 91]. Hepatology. 2005;42(suppl 1):232A.
37. Ghany M, Lutchman G, Kleiner D, et al. Lamivudine and adefovir versus adefovir alone for HBeAg-positive chronic hepatitis B [abstract 1005]. Hepatology. 2005;42(suppl 1):591A-592A.
38. van Bömmel F, Feucht HH, Möller B, et al. Tenofovir rescue for patients with lamivudine resistant HBV infection with suboptimal virologic response to adefovir [abstract 1000]. Hepatology. 2005;42(suppl 1):589A-590A.
39. van Bömmel F, Mauss S, Zollner B, et al. Long-term effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir [abstract 184]. Hepatology. 2005;42(suppl 1):269A.
40. Mazzaferro V, Ragalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;34:693-699.
41. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765-774.
42. Hong S, Fontana RJ, Erin R, et al. Total tumor burden is predictive of survival and recurrence after liver transplantation for hepatocellular carcinoma: a caution for expansion of Milan criteria [abstract 105]. Hepatology. 2005; 42(suppl 1):238A-239A.
43. Yao FY, Bass NM, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: a 4-year prospective study validating expanding criteria based on pre-operative staging [abstract 4]. Hepatology. 2005;42(suppl 1):197A.
44. Kulik LM, Freise CE, Lok AS, et al. A comparison of adult living donor (LDLT) to deceased donor liver transplant (DDLT) for hepatocellular carcinoma (HCC): data from the A2ALL study [abstract 9]. Hepatology. 2005;42(suppl 1):199A.
45. Reddy R, Gaglio P, Keeffe E, et al. Characteristics and outcomes following liver transplantation (OLT) in patients with HBV-related hepatocellular carcinoma (HCC): data from the U.S. HBV-OLT study [abstract 108]. Hepatology. 2005; 42(suppl 1):240A.
46. Freeman R, Edwards EB, Harper AM. Trends in MELD score and transplantation rates under the MELD system [abstract 19]. Hepatology. 2005;42(suppl 1):203A.
47. Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores [abstract 22]. Hepatology. 2005;42(suppl 1):204A-205A.
48. Arjal R, McCashland T, Smith AD, et al. Variation in model for end-stage liver disease (MELD) score between transplant centers based on laboratory method for determination of international normalized ratio (INR) [abstract 23]. Hepatology. 2005;42(suppl 1):205A.
49. Behari J, Swaminathan V, Bryce C, et al. Racial differences and model for end-stage liver disease (MELD) scores, change in MELD (delta MELD) on the transplant list and waiting times of liver transplant recipients in the United States [abstract 24]. Hepatology. 2005;42(suppl 1): 205A.
50. Pedersen RA, Kim WR, Therneau T, et al. Are retransplant candidates disadvantaged under the MELD-based organ allocation system [abstract 5]? Hepatology. 2005;42(suppl 1):197A-198A.
51. Lai C-L, Gane E, Liaw Y-F, et al. Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (The GLOBE Study) [abstract 92]. Hepatology. 2005;42(suppl 1):232A-233A.
52. Sullivan-Bolyai J, Lim SG, Lee KS, et al. Safety, tolerability, antiviral activity, and pharmacokinetics of pradefovir mesylate in patients with chronic hepatitis B virus infection: 24-week interim analysis of a phase 2 study [abstract LB07]. Hepatology. 2005;42(suppl 1):78A.
53. Gish RG, Chang T-T, De Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HbeAg seroconversion through 96 weeks of treatment in HbeAg(+) chronic hepatitis B patients (study ETV-022) [abstract 181]. Hepatology. 2005;42(suppl 1):267A.
54. Lai C-L, Gane E, Liaw Y-F, et al. Telbivudine (LDT) vs lamivudine for chronic hepatitis B: first-year results from the international phase III Globe trial [abstract LB01]. Hepatology. 2005; 42(suppl 1):748A.
55. Yoo BC, Kim JH, Lee KS, et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HbeAg(+) chronic hepatitis B patients [abstract 186]. Hepatology. 2005;42(suppl 1):210A.
56. de Franchis R, Eisen GM, Eliakim R, et al. Esophageal capsule endoscopy (pillcam eso) is comparable to traditional endoscopy for screening/surveillance for esophageal varices [abstract 37]. Hepatology. 2005;42(suppl 1):210A.
57. Bruno S, Stroffolini T, Bollani S, et al. Long-term outcome of patients with HCV-related, Child's class A treated with interferon-alpha (IFN): the impact of sustained virologic response (SVR) on hepatocellular carcinoma (HCC) occurrence and mortality [abstract 85]. Hepatology. 2005; 42(suppl 1):229A.